Table 3.
Percentage of Subjects with Titer ≥40 and Percentage with four-fold increase over baseline in HAI Assay
| Percentage of Subjects with Titer ≥40 | ||||
|---|---|---|---|---|
| Influenza Antigen | Week | LAIV | TIV | (TIV-LAIV)1 |
| A H1N1 | 0 | 42% (49/116) | 46% (55/119) | 0.04 (−0.09, 0.17) |
| 4 | 63% (72/114) | 67% (75/112) | 0.04 (−0.09, 0.16) | |
| 24 | 45% (50/110) | 55% (64/116) | 0.10 (−0.03, 0.23) | |
| A H3N2 | 0 | 78% (90/116) | 88% (105/119) | 0.11 (0.01, 0.20)* |
| 4 | 92% (105/114) | 96% (108/112) | 0.04 (−0.02, 0.12) | |
| 24 | 95% (104/110) | 97% (113/116) | 0.03 (−0.03, 0.09) | |
| B | 0 | 23% (27/116) | 37% (44/119) | 0.14 (0.02, 0.25)* |
| 4 | 33% (38/114) | 69% (77/112) | 0.35 (0.23, 0.47)* | |
| 24 | 32% (35/110) | 63% (73/116) | 0.31 (0.18, 0.43)* | |
| Percentage of Subjects with four-fold increase over baseline | ||||
| Influenza Antigen | Week | LAIV | TIV | (TIV-LAIV)1 |
| A H1N1 | 4 | 32% (37/114) | 33% (37/112) | 0.01 (−0.12, 0.13) |
| 24 | 22% (24/110) | 16% (19/116) | −0.05 (−0.16, 0.05) | |
| A H3N2 | 4 | 14% (16/114) | 44% (49/112) | 0.30 (0.18, 0.41)* |
| 24 | 29% (32/110) | 34% (39/116) | 0.05 (−0.08, 0.17) | |
| B | 4 | 11% (12/114) | 34% (38/112) | 0.23 (0.13, 0.34)* |
| 24 | 11% (12/110) | 22% (25/116) | 0.11 (0.01, 0.20)* | |
1
The difference in rate between TIV and LAIV and its 95% confidence interval.
*
Indicates significant difference with p<0.05